Logo

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

Share this

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

Shots:

  • Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera- whereby Santhera shall replace Idorsia as a party to the agreement.  Santhera to get an exclusive license- including sublicensing rights- for vamorolone in all indications globally- including Japan and South Korea and a share in expected PR voucher
  • In exchange for the revised license rights- Idorsia will receive 366-667 Santhera’s shares and an exchangeable note of $10.9M and is eligible to receive development & commercial milestones on sales of therapy. ReveraGen will receive $7M- in monthly installments of up to $500-000- to fund the ongoing clinical development of vamorolone
  • Santhera exercises the option to get global rights to vamorolone in DMD and all other indications. ReveraGen is evaluating Vamorolone in P-IIb VISION-DMD study and expects the completion of enrollment shortly

- Click Here ­ Ref: PRNewswire | Image: Santhera

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions